{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:41:16Z","timestamp":1769074876915,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2007,8,1]]},"DOI":"10.1532\/ijh97.07052","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T12:22:02Z","timestamp":1190118122000},"page":"150-157","source":"Crossref","is-referenced-by-count":17,"title":["A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome: Presence of CD55-CD59- Blood Cells Predicts Platelet Response"],"prefix":"10.1007","volume":"86","author":[{"given":"Takayuki","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yataro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Teramura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Motoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takatoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Omine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. <i>Br J Haematol.<\/i> 1982;51:189-199."},{"key":"E00002","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. <i>Blood.<\/i> 1997;89:2079-2088."},{"key":"E00003","unstructured":"Alessandrino EP, Amadori S, Barosi G, et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. <i>Haematologica.<\/i> 2002;87:1286-1306."},{"key":"E00004","unstructured":"Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. <i>Br J Haematol.<\/i> 2003;120:187-200."},{"key":"E00005","unstructured":"Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood.<\/i> 2004;104:579-585."},{"key":"E00006","unstructured":"Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. <i>Blood.<\/i> 1998;92:68-75."},{"key":"E00007","unstructured":"Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. <i>Blood.<\/i> 2004;104:321-327."},{"key":"E00008","unstructured":"Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. <i>Blood.<\/i> 2000;96:3671-3674."},{"key":"E00009","unstructured":"List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. <i>N Engl J Med.<\/i> 2005;352:549-557."},{"key":"E00010","unstructured":"List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. <i>N Engl J Med.<\/i> 2006;355:1456-1465."},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. <i>Cancer Control.<\/i> 2006;13(suppl):4-11.","DOI":"10.1177\/107327480601304s02"},{"key":"E00012","unstructured":"Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. <i>Ann Intern Med.<\/i> 2002;137:156-163."},{"key":"E00013","unstructured":"Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with lowrisk myelodysplastic syndromes. <i>Leukemia.<\/i> 2004;18:460-465."},{"key":"E00014","unstructured":"Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia. <i>Br J Haematol.<\/i> 2003;120:679-684."},{"key":"E00015","unstructured":"Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. <i>Ann Intern Med.<\/i> 1999;131:401-408."},{"key":"E00016","unstructured":"Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. <i>Blood.<\/i> 2002;100:1570-1574."},{"key":"E00017","unstructured":"Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. <i>Br J Haematol.<\/i> 1998;100:304-309."},{"key":"E00018","unstructured":"Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. <i>Haematologica.<\/i> 2000;85:133-138."},{"key":"E00019","unstructured":"Dixit A, Chatterjee T, Mishra P, et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. <i>Ann Hematol.<\/i> 2005;84:565-568."},{"key":"E00020","unstructured":"Ogata M, Ohtsuka E, Imamura T, et al. Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review. <i>Int J Hematol.<\/i> 2004;80:35-42."},{"key":"E00021","unstructured":"Asano Y, Maeda M, Uchida N, et al. Immunosuppressive therapy for patients with refractory anemia. <i>Ann Hematol.<\/i> 2001;80:634-638."},{"key":"E00022","unstructured":"Atoyebi W, Bywater L, Rawlings L, Brunskill S, Littlewood TJ. Treatment of myelodysplasia with oral cyclosporin. <i>Clin Lab Haematol.<\/i> 2002;24:211-214."},{"key":"E00023","unstructured":"Chen S, Jiang B, Da W, Gong M, Guan M. Treatment of myelodysplastic syndrome with cyclosporin A. <i>Int J Hematol.<\/i> 2007;85:11-17."},{"key":"E00024","unstructured":"Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. <i>Leuk Res.<\/i> 2003;27:783-788."},{"key":"E00025","unstructured":"Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. <i>Blood.<\/i> 2002;100:3897-3902."},{"key":"E00026","unstructured":"Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. <i>Blood.<\/i> 2006;107:1308-1314."},{"key":"E00027","unstructured":"Matsutani T, Yoshioka T, Tsuruta Y, Iwagami S, Suzuki R. Analysis of TCRAV and TCRBV repertoires in healthy individuals by microplate hybridization assay. <i>Hum Immunol.<\/i> 1997;56:57-69."},{"key":"E00028","unstructured":"Yoshioka T, Matsutani T, Iwagami S, et al. Polyclonal expansion of TCRBV2-and TCRBV6-bearing T cells in patients with Kawasaki disease. <i>Immunology.<\/i> 1999;96:465-472."},{"key":"E00029","unstructured":"Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. <i>Blood.<\/i> 1998;91:340-346."},{"key":"E00030","unstructured":"Verfuerth S, Peggs K, Vyas P, Barnett L, O'Reilly RJ, Mackinnon S. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. <i>Blood.<\/i> 2000;95:3990-3995."},{"key":"E00031","unstructured":"Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. <i>Int J Hematol.<\/i> 1993;57:87-97."},{"key":"E00032","unstructured":"Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. <i>Leukemia.<\/i> 1999;13:393-399."},{"key":"E00033","unstructured":"Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. <i>Blood.<\/i> 2003;101:2156-2158."},{"key":"E00034","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. <i>J Clin Oncol.<\/i> 1999;17:3835-3849."},{"key":"E00035","unstructured":"Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. <i>Blood.<\/i> 2005;106:2633-2640."},{"key":"E00036","unstructured":"Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. <i>Br J Haematol.<\/i> 1998;102:1314-1322."},{"key":"E00037","unstructured":"Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. <i>Blood.<\/i> 2002;100:3639-3645."},{"key":"E00038","unstructured":"Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. <i>Blood.<\/i> 1999;93:3008-3016."}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.07052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T23:19:29Z","timestamp":1556839169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.07052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8,1]]}},"alternative-id":["B825VRU20K835K14"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.07052","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}